No abstract available
Keywords:
ALK; Alectinib hepatotoxicity; CNS efficacy of brigatinib; CNS relapse; Dose-escalated brigatinib.
MeSH terms
-
Adult
-
Anaplastic Lymphoma Kinase / genetics
-
Brain Neoplasms / pathology
-
Brain Neoplasms / secondary
-
Brain Neoplasms / therapy*
-
Carbazoles / administration & dosage
-
Carbazoles / adverse effects
-
Carcinoma, Non-Small-Cell Lung / genetics
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Carcinoma, Non-Small-Cell Lung / therapy*
-
Chemical and Drug Induced Liver Injury / etiology
-
Combined Modality Therapy
-
Dose-Response Relationship, Drug
-
Female
-
Humans
-
Lung Neoplasms / genetics
-
Lung Neoplasms / pathology
-
Lung Neoplasms / therapy*
-
Neoplasm Recurrence, Local
-
Organophosphorus Compounds / administration & dosage
-
Piperidines / administration & dosage
-
Piperidines / adverse effects
-
Protein Kinase Inhibitors / administration & dosage*
-
Protein Kinase Inhibitors / adverse effects
-
Pyrimidines / administration & dosage
-
Radiosurgery
-
Treatment Outcome
Substances
-
Carbazoles
-
Organophosphorus Compounds
-
Piperidines
-
Protein Kinase Inhibitors
-
Pyrimidines
-
ALK protein, human
-
Anaplastic Lymphoma Kinase
-
brigatinib
-
alectinib